+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Graves Disease Market by Diagnosis, Treatment, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Graves Disease Market by Diagnosis, Treatment, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Graves Disease Market by Diagnosis, Treatment, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5674290
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Graves Disease Market grew from USD 583.85 million in 2023 to USD 613.51 million in 2024. It is expected to continue growing at a CAGR of 5.42%, reaching USD 844.89 million by 2030.

Graves' Disease is an autoimmune disorder characterized by the overproduction of thyroid hormones, a condition known as hyperthyroidism. The scope of market research for Graves' Disease encompasses a wide range of aspects, from early diagnosis to advanced treatment options and patient management strategies. The rising prevalence of autoimmune disorders, increasing awareness of thyroid complications, and advancements in diagnostic and therapeutic technologies drive the necessity and application of this market research. End-use sectors include healthcare providers, pharmaceutical companies, and diagnostic centers, which depend on the latest insights to advance their offerings. Key growth influencers include the development of innovative treatments such as biological drugs and better-radioactive iodine therapy, alongside increased government healthcare expenditure and initiatives to promote research and awareness. However, challenges like high costs associated with treatment, limited availability of advanced healthcare facilities in developing regions, and potential side effects of existing therapies can impede market growth. Opportunities lie in personalized medicine approaches, ongoing R&D to optimize biologics, and enhancement of non-invasive diagnostic tools. Recommendations include investing in telemedicine and digital health technologies, aligning with policy reforms to improve healthcare infrastructure, and focusing on patient-centric care models to increase engagement and adherence to treatment plans. Limiting factors include the lack of sufficient funding for research and resistance to change within existing medical practices. Innovation can flourish by investigating autoimmune pathogeneses and employing AI for predictive diagnostics, enhancing both the efficacy and precision of treatments. The market exhibits a trend towards integrated healthcare approaches, leveraging digital tools to improve disease management and patient outcomes. Thus, engagement in cross-sector partnerships and continuous investment in cutting-edge research are vital to harness growth potentials in the Graves' Disease market landscape.

Understanding Market Dynamics in the Graves Disease Market

The Graves Disease Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of autoimmune disorders globally
    • Increasing awareness among population with rising government initiatives
    • Growing demand for personalized medecine
  • Market Restraints
    • High cost associated with advanced therapeutics and diagnostics
  • Market Opportunities
    • Ongoing research and development activities for advanced therapies
    • Emerging collaboration between research institutes and biotech firms
  • Market Challenges
    • Stringent regulatory environments and complex approval procedures

Exploring Porter’s Five Forces for the Graves Disease Market

Porter’s Five Forces framework further strengthens the insights of the Graves Disease Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Graves Disease Market

External macro-environmental factors deeply influence the performance of the Graves Disease Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Graves Disease Market

The Graves Disease Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Graves Disease Market

The Graves Disease Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Graves Disease Market

The Graves Disease Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Graves Disease Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AdvanceCor GmbH, Amgen Inc., Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GSK plc, Immunovant, Inc., Jubilant Pharma Holdings Inc., Lannett Company, Inc., Lupin Limited, Medtronic PLC, Merck KGaA, Novartis AG, Omeros Corp, OSE Immunotherapeutics SA, Protheragen Inc, RLC Labs, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Viatris Inc., and Zenas BioPharma, Inc..

Market Segmentation & Coverage

This research report categorizes the Graves Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Diagnosis
    • Blood Tests
      • Free T4 & T3 Levels
      • Thyroid-Stimulating Hormone (TSH) Levels
      • TSH Receptor Antibodies (TSH-RAb)
    • Imaging Tests
      • CT or MRI Scans
      • Radioactive Iodine Uptake
      • Thyroid Ultrasound
    • Physical Examination
  • Treatment
    • Adjunctive Treatments
    • Medications
      • Anti-thyroid Drugs
      • Beta-Blockers
        • Atenolol
        • Propranolol
    • Radioactive Iodine Therapy
    • Surgery
  • Route of Administration
    • Intravenous
    • Oral
    • Surgical Intervention
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • End User
    • Healthcare Providers
    • Hospitals & Clinics
    • Individual Patients
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of autoimmune disorders globally
5.1.1.2. Increasing awareness among population with rising government initiatives
5.1.1.3. Growing demand for personalized medecine
5.1.2. Restraints
5.1.2.1. High cost associated with advanced therapeutics and diagnostics
5.1.3. Opportunities
5.1.3.1. Ongoing research and development activities for advanced therapies
5.1.3.2. Emerging collaboration between research institutes and biotech firms
5.1.4. Challenges
5.1.4.1. Stringent regulatory environments and complex approval procedures
5.2. Market Segmentation Analysis
5.2.1. Treatment: Proliferation of radioactive iodine therapy for Graves' disease treatment
5.2.2. Route of Administration: Growing application of intravenous administration for acute management of Graves' disease
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Graves Disease Market, by Diagnosis
6.1. Introduction
6.2. Blood Tests
6.2.1. Free T4 & T3 Levels
6.2.2. Thyroid-Stimulating Hormone (TSH) Levels
6.2.3. TSH Receptor Antibodies (TSH-RAb)
6.3. Imaging Tests
6.3.1. CT or MRI Scans
6.3.2. Radioactive Iodine Uptake
6.3.3. Thyroid Ultrasound
6.4. Physical Examination
7. Graves Disease Market, by Treatment
7.1. Introduction
7.2. Adjunctive Treatments
7.3. Medications
7.3.1. Anti-thyroid Drugs
7.3.2. Beta-Blockers
7.3.2.1. Atenolol
7.3.2.2. Propranolol
7.4. Radioactive Iodine Therapy
7.5. Surgery
8. Graves Disease Market, by Route of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Surgical Intervention
9. Graves Disease Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
9.5. Specialty Pharmacies
10. Graves Disease Market, by End User
10.1. Introduction
10.2. Healthcare Providers
10.3. Hospitals & Clinics
10.4. Individual Patients
11. Americas Graves Disease Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Graves Disease Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Graves Disease Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. IBSA USA Renews Alliance with Golfer Azahara Muñoz to Boost Awareness for FDA-Approved Tirosint-SOL, the Hypothyroidism Treatment Offering Unmatched Flexibility and Convenience
14.3.2. Innovent Biologics' Advancement Anti-IGF-1R Antibody IBI311 Secures Priority Review for Thyroid Eye Disease in China, Supporting Major Clinical Advances and Global Expansion
14.3.3. Amgen Moves to Advance Graves' Disease Treatment with EU Approval of Teprotumumab for Thyroid Eye Disease; Plans for Long-Term Market Expansion and Patient Care Enhancements
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. GRAVES DISEASE MARKET RESEARCH PROCESS
FIGURE 2. GRAVES DISEASE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. GRAVES DISEASE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. GRAVES DISEASE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. GRAVES DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GRAVES DISEASE MARKET DYNAMICS
TABLE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY CT OR MRI SCANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADJUNCTIVE TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTI-THYROID DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GRAVES DISEASE MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GRAVES DISEASE MARKET SIZE, BY PROPRANOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GRAVES DISEASE MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GRAVES DISEASE MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL GRAVES DISEASE MARKET SIZE, BY INDIVIDUAL PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. CANADA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 72. CANADA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 73. CANADA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 74. CANADA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. CANADA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 76. CANADA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 77. CANADA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. CANADA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. CANADA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. MEXICO GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. MEXICO GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. MEXICO GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. MEXICO GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. CHINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 119. CHINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 120. CHINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 121. CHINA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. CHINA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 123. CHINA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 124. CHINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. CHINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. CHINA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. INDIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 128. INDIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 129. INDIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 130. INDIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. INDIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 132. INDIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 133. INDIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. INDIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. INDIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 141. INDONESIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 142. INDONESIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. INDONESIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. INDONESIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. JAPAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 146. JAPAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 147. JAPAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 148. JAPAN GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. JAPAN GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 150. JAPAN GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 151. JAPAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. JAPAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. JAPAN GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 159. MALAYSIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 160. MALAYSIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. MALAYSIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. MALAYSIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SINGAPORE GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 195. TAIWAN GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 196. TAIWAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. TAIWAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. TAIWAN GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. THAILAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 200. THAILAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 201. THAILAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 202. THAILAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 203. THAILAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 204. THAILAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 205. THAILAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. THAILAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. THAILAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 213. VIETNAM GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 214. VIETNAM GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. VIETNAM GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. VIETNAM GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 227. DENMARK GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 228. DENMARK GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 229. DENMARK GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 230. DENMARK GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. DENMARK GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 232. DENMARK GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 233. DENMARK GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. DENMARK GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. DENMARK GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. EGYPT GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 237. EGYPT GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 238. EGYPT GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 239. EGYPT GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 240. EGYPT GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 241. EGYPT GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 242. EGYPT GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. EGYPT GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. EGYPT GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. FINLAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 247. FINLAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 248. FINLAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 249. FINLAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 250. FINLAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 251. FINLAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. FINLAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. FINLAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. FRANCE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 255. FRANCE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 256. FRANCE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 257. FRANCE GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 258. FRANCE GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 259. FRANCE GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 260. FRANCE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. FRANCE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. FRANCE GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. GERMANY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 264. GERMANY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 265. GERMANY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 266. GERMANY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 267. GERMANY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 268. GERMANY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 269. GERMANY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. GERMANY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. GERMANY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 278. ISRAEL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. ISRAEL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. ISRAEL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. ITALY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 282. ITALY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 283. ITALY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 284. ITALY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 285. ITALY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 286. ITALY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 287. ITALY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. ITALY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. ITALY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. NORWAY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 309. NORWAY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 310. NORWAY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 311. NORWAY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 312. NORWAY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 313. NORWAY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 314. NORWAY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. NORWAY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 316. NORWAY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. POLAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 318. POLAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 319. POLAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 320. POLAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 321. POLAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 322. POLAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 323. POLAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. POLAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. POLAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 326. QATAR GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 327. QATAR GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 328. QATAR GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 329. QATAR GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 330. QATAR GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 331. QATAR GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 332. QATAR GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333. QATAR GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 334. QATAR GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 335. RUSSIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 336. RUSSIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 337. RUSSIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 338. RUSSIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 339. RUSSIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 340. RUSSIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 341. RUSSIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 342. RUSSIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 343. RUSSIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 344. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 345. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 346. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 347. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 348. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 349. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 350. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 351. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 352. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 353. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 354. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 355. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 356. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 357. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 358. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
TABLE 359. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 360. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 361. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 362. SPAIN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 363. SPAIN

Companies Mentioned

The leading players in the Graves Disease market, which are profiled in this report, include:
  • Abbott Laboratories
  • AbbVie Inc.
  • AdvanceCor GmbH
  • Amgen Inc.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Immunovant, Inc.
  • Jubilant Pharma Holdings Inc.
  • Lannett Company, Inc.
  • Lupin Limited
  • Medtronic PLC
  • Merck KGaA
  • Novartis AG
  • Omeros Corp
  • OSE Immunotherapeutics SA
  • Protheragen Inc
  • RLC Labs, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.
  • Zenas BioPharma, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 613.51 Million
Forecasted Market Value ( USD ) by 2030 $ 844.89 Million
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Graves' Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Graves' Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 137 Pages
  • Global
From
Graves' Disease - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Graves' Disease - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Graves Orbitopathy - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Graves Orbitopathy - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Carbimazole Market by Indication, End users, Distribution Channel - Global Forecast 2025-2030 - Product Image

Carbimazole Market by Indication, End users, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Thyroid Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030 - Product Image

Thyroid Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

  • Report
  • 300 Pages
  • Global
From

About the Graves Disease Market

Graves Disease is a type of autoimmune disorder that affects the thyroid gland. It is the most common cause of hyperthyroidism, a condition in which the thyroid produces too much of the hormone thyroxine. Symptoms of Graves Disease include weight loss, increased appetite, rapid heart rate, and bulging eyes. Treatment typically involves medications to reduce the production of thyroxine, as well as radioactive iodine therapy to destroy the thyroid gland. Allergy and Immunology is a medical specialty that focuses on the diagnosis and treatment of allergies and immune system disorders. Allergy and Immunology specialists are trained to diagnose and treat Graves Disease, as well as other autoimmune disorders. They may also provide advice on lifestyle changes to help manage the condition. Companies in the Graves Disease market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.